A personalised approach to oesophagogastric cancers emerging and requires a rapid and multi-disciplinary development.

The care of oesophagogastric cancers is complex and resistance to loco-regional and systemic treatments is frequent, meaning new clinical and epidemiological studies, relying on biological and tumor collection, must be put in place in a grand scale. The main scientific questions that can be addressed are :

  • identification of new prognostic and predictive factors,
  • understanding of underlying mechanisms and the development of new drugs,
  • validation of promising predictive markers to anti-tumoral therapy,
  • evaluation of the impact of current treatment strategies in the overall population and sub-groups,
  • identifier of epidemiological and human and social science determinants which delay on the delay to access to care and the commencement of treatment, and
  • to better understand the therapeutic strategies and their impact on the quality of life for patients.

The creation of a large prospective clinic-biological database dedicated to oesophagogastric cancers is required for the development of all such projects.

Amelioration access care

The challenges of our research are to investigate in an initial phase the causes of treatment resistance observed in oesophagogastric tumours.

This will give us the opportunity to improve treatments and in the long term to provide a personalized treatment to each patient based on characteristics of each cancer and to significantly improve survival for this group of cancers.

In a second phase, we want to significantly  reduce the time for patients to a access care by reducing the time between first symptom and first consultation/first treatment.

By reducing this time, we will diagnose cancers at earlier stages and thus improve patient survival.